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The European cystic fibrosis patient registry: The power of sharing dataThis special supplement of the Journal of Cystic Fibrosis is
the first of two supplements dedicated to the European
Coordination Action for Research in Cystic Fibrosis (Euro-
CareCF) project. Funded by the Sixth Framework Programme
of the European Commission, EuroCareCF provided indivi-
duals working to defeat the common, life-shortening genetic
disease cystic fibrosis (CF) with opportunities to interact,
exchange information and collaborate to achieve common
goals. The major goals of the project were first, to improve the
survival and quality of life of CF patients and second, to
optimize clinical management and therapy development.
To achieve its goals, EuroCareCF was organized into a series
of eight workpackages addressing different areas of CF research
and patient care (Fig. 1). These areas ranged from basic research
and therapy development to clinical research, patient care and
the development of a European CF patient registry. Through a
variety of activities, such as meetings, workshops and “hands-
on” training courses, workpackages produced reports and
consensus guidelines, built networks of CF professionals,
provided expert training and distributed key resources to the
CF community. Some reports and consensus guidelines have
already been published (e.g. Refs. 1–6). Most will be published
in the second EuroCareCF supplement for the Journal of Cystic
Fibrosis. However, this supplement is devoted to the report of
EuroCareCF workpackage 2 (European CF Patient Registry) on
the demographics of CF in 35 European countries (7).
The aim of EuroCareCF workpackage 2 was to create a
uniform and ethically compliant European registry of CF
patients. At the outset of the EuroCareCF project, the scope of
this Registry was limited to CF patients from 22 countries
within the European Union. However, through collaboration
with the European Cystic Fibrosis Society (ECFS), the scope of
the Registry was enlarged substantially to include CF patients
from other countries in Europe, member and non-member states
of the European Union alike.
The scale of the task facing EuroCareCF workpackage 2 was
enormous. First, it included framing templates and guidelines
for obtaining patient consent in each country that satisfied the
requirements of the European Data Protection Directive 95/46/
EC, while remaining compliant with local laws and ethics (see
the webpages of EuroCareCF workpackage 2; http://www.
eurocarecf.eu/). These consent templates and procedures
continue to be used by the ECFS in their management of the
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opean_cf_registry/ethics_conf). Second, obtaining the approval
of CF patients to collect anonymised data. Third, agreeing with
both the CF Foundation (USA) and the ECFS common
definitions for demographic variables to ensure that the
collected data would be truly comparable, while at the same
time making the data “future-proof” to facilitate international
comparisons. Fourth, collecting and analysing demographic
data for CF patients from 35 European countries. Finally,
producing a report on the demographics of CF in Europe (7).
The enthusiasm to contribute to the European CF Patient
Registry was tremendous. Prior to the start of EuroCareCF, with
the exception of a few countries, most countries in Europe
lacked formal CF patient registries. To facilitate the analysis and
comparison of data from different European countries, Euro-
CareCF workpackage 2 focused on collecting demographic data
(e.g. month and year of birth, age at diagnosis, gender and
genotype). In total, forty one European countries (Armenia,
Austria, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Cyprus,
Czech Republic, Denmark, Estonia, France, Georgia, Germany,
Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia,
Lithuania, Luxembourg, Macedonia, Malta, Moldova,
Netherlands, Norway, Poland, Portugal, Romania, Russia,
Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland,
Turkey, Ukraine and United Kingdom) joined the European
CF Patient Registry. Of these countries, all but six countries
contributed data for the EuroCareCF report on the demograph-
ics of CF in Europe (7). A special feature of this report is that
demographic data for individual countries are compared side-
by-side with demographic data for all of Europe (i.e. 29,095
patients from 35 countries).
In his commentary (8), Nick Fahy (Head of the Health
Information Unit, European Commission, Luxembourg)
explains the significance of this report by EuroCareCF work-
package 2 as well as their analysis of the effects of European
Union membership on the demographics of CF in Europe (9).
My own view is that the European CF Patient Registry is of
critical importance for the care of CF patients in Europe,
providing vital information with which to assess the perfor-
mance of healthcare systems in individual countries. Analysis of
collected data permits the identification of CF centres that
perform especially well with the result that best practice in
patient care can be shared widely to the benefit of all CF patients.
The Registry also has a crucial role to play in the identification ofd by Elsevier B.V. All rights reserved.
Fig. 1. The organization of the EuroCareCF project. EuroCareCF consisted of
eight workpackages undertaking programmes of work to address specific
aspects of patient care and therapy development and a coordinating work-
package that managed the project, promoted interactions between project
participants and stakeholders and communicated with the European Commis-
sion (EC). The eight workpackages of EuroCareCF were Optimising Patient
Care & CF Team Work; European Cystic Fibrosis Patient Registry;
Coordination of Clinical Research; Small and Medium-Sized Enterprises
(SMEs) Group; Novel Therapies; Animal Models; Integration of Fundamental
Research and Ethical/Legal/Social Issues.
S2 EditorialCF patients for mutation-specific clinical trials of new therapies
for CF. The close cooperation that has developed between the
European CF Patient Registry and the European Clinical Trial
Network (10) is therefore very welcome. Given the importance
of the European CF Patient Registry, I am especially delighted
that the ECFS has agreed to fund and manage this Registry after
the end of the EuroCareCF project.
During the course of the project, EuroCareCF workpackage
2 received requests from several countries outside of Europe to
join the European CF Patient Registry. Because of the nature of
the project and its funding from the European Commission, it
was regrettably not possible for these countries to join the
Registry. In the future, the CF community should strive towards
a global CF Patient registry with common data definitions. The
development of such a database would improve further patient
care and therapy development. It would also provide another
example of CF serving as a paradigm for other rare diseases.
I would like to take this opportunity to thank many wonderful
colleagues for their wide-ranging contributions to the success of
the European CF Patient Registry. Anil Mehta, Milan Macek and
Gita Mehta, the leader, deputy leader and project manager,
respectively, of EuroCareCF workpackage 2, who undertook all
the work listed above, and much more besides, to establish the
European CF Patient Registry. Marie Johannesson and Stuart
Elborn, Presidents of the ECFS during the period of the
EuroCareCF project, for their vision of a European CF Patient
Registry and their commitment to supporting the Registry after
the end of funding from the European Commission, respectively.
The Registry Steering Committee, including Hanne Olesen, EitanKerem,Martin Stern and Laura Viviani aswell as colleagues from
the ECFS Registry Working Group for generously sharing data
and developing data standards. Bob Beall, Preston Campbell,
Bruce Marshall and colleagues from the US CF Foundation for
generously sharing their registry software, PortCF and for
providing invaluable help and advice about CF patient registries.
Herman Nys and Kris Dierickx of EuroCareCF workpackage
8 (Ethical/Legal/Social Issues) for their advice about patient
consent. Representatives of 41 European countries for generously
agreeing to share CF patient data to build a truly European CF
Patient Registry. EuroCareCF was supported by the European
Union Sixth Framework Programme (contract no. LSHM-CT-
2005-018932, EuroCareCF).References
[1] Castellani C, Southern KW, Brownlee K, et al. European best practice
guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009;8:
153–73.
[2] Goubau C, Wilschanski M, Skalická V, et al. Phenotypic characterisation
of patients with intermediate sweat chloride values: towards validation of
the European diagnostic algorithm for cystic fibrosis. Thorax 2009;64:
683–91.
[3] Hogardt M, Ulrich J, Riehn-Kopp H, Tümmler B. EuroCareCF quality
assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin
Microbiol 2009;47:3435–8.
[4] Becq F. Cystic fibrosis transmembrane conductance regulator modulators
for personalized drug treatment of cystic fibrosis: progress to date. Drugs
2010;70:241–59.
[5] Scholte BJ, Colledge WH, Wilke M, de Jonge H. Cellular and animal
models of cystic fibrosis, tools for drug discovery. Drug Discov Today Dis
Models 2006;3:251–9.
[6] Pinxten W, Dierickx K, Nys H. Ethical principles and legal requirements
for pediatric research in the EU: an analysis of the European normative and
legal framework surrounding pediatric clinical trials. Eur J Pediatr
2009;168:1225–34.
[7] Mehta G, Macek M Jr, Mehta A. European Registry Working Group.
Cystic fibrosis across Europe: EuroCareCF analysis of demographic data
from 35 countries. J Cyst Fibros 2010;9:S5–S21 (this issue).
[8] Fahy N. Commentary. J Cyst Fibros 2010;9:S3–4 (this issue).
[9] McCormick J, Mehta G, Olesen HV, Viviani L, Macek M Jr, Mehta A;
European Registry Working Group. Comparative demographics of the
European cystic fibrosis population: a cross-sectional database analysis.
Lancet 2010;375:1007–13.
[10] De Boeck K, Bulteel V, Tiddens H, et al. Guideline on the design and
conduct of CF clinical trials: the European Cystic Fibrosis Society Clinical
Trial Network (ECFS-CTN). J Cyst Fibros 2010 (Second EuroCareCF
Supplement).
David N. Sheppard
School of Physiology and Pharmacology,
University of Bristol, Medical Sciences Building,
University Walk, Bristol BS8 1TD, UK
Tel.: +44 117 331 2290; fax: +44 117 331 2288.
E-mail address: D.N.Sheppard@bristol.ac.uk.
